0
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Health Agencies Update |  April 24, 2013
Diabetes Drugs Investigated
Bridget M. Kuehn, MSJ
JAMA. 2013;309(16):1674. doi:10.1001/jama.2013.4243.
Medical News and Perspectives |  April 03, 2013
Cutting Medicare Costs Will Require Multipronged Approach
Bridget M. Kuehn, MSJ
JAMA. 2013;309(13):1334-1335. doi:10.1001/jama.2013.2771.
Medical News and Perspectives |  April 03, 2013
More Patients Get Good Diabetes Control, but Only a Minority Meet All Goals
Mike Mitka, MSJ
JAMA. 2013;309(13):1335-1336. doi:10.1001/jama.2013.2414.
Editorial |  December 19, 2012
A Look Ahead at the Future of Diabetes Prevention and Treatment
David E. Arterburn, MD, MPH; Patrick J. O’Connor, MD, MA, MPH
JAMA. 2012;308(23):2517-2518. doi:10.1001/jama.2012.144749.
Original Contribution |  December 19, 2012
Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes
Edward W. Gregg, PhD; Haiying Chen, PhD; Lynne E. Wagenknecht, DrPH; et al.
JAMA. 2012;308(23):2489-2496. doi:10.1001/jama.2012.67929.
INCLUDES: , Supplemental Content
Caring for the Critically Ill Patient |  October 24, 2012 FREE
Neurocognitive Development of Children 4 Years After Critical Illness and Treatment With Tight Glucose Control:  A Randomized Controlled Trial
Dieter Mesotten, MD, PhD; Marijke Gielen, MD; Caroline Sterken, MPsych; et al.
JAMA. 2012;308(16):1641-1650. doi:10.1001/jama.2012.12424.
INCLUDES: , Supplemental Content
Editorial |  October 24, 2012
Pediatric Critical Care, Glycemic Control, and Hypoglycemia:  What Is the Real Target?
Robert C. Tasker, MBBS, MD
JAMA. 2012;308(16):1687-1688. doi:10.1001/jama.2012.14151.
Original Contribution |  September 19, 2012 FREE
Exercise Dose and Diabetes Risk in Overweight and Obese Children:  A Randomized Controlled Trial
Catherine L. Davis, PhD; Norman K. Pollock, PhD; Jennifer L. Waller, PhD; et al.
JAMA. 2012;308(11):1103-1112. doi:10.1001/2012.jama.10762.
Lab Reports |  September 05, 2012
Metformin Benefits the Brain
Tracy Hampton, PhD
JAMA. 2012;308(9):853. doi:10.1001/2012.jama.10598.
Medical News and Perspectives |  June 20, 2012
IOM Urges FDA to Be More Aggressive in Monitoring Safety of Approved Drugs
Bridget M. Kuehn
JAMA. 2012;307(23):2475-2476. doi:10.1001/jama.2012.5993.

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

From The JAMA Network
JAMA Internal Medicine
Viewpoint  |  May 13, 2013
Adulterated Sexual Enhancement Supplements:  More Than Mojo
Pieter A. Cohen, MD; Bastiaan J. Venhuis, PhD
JAMA Internal Medicine
Editorial  |  April 22, 2013
Trust in the Medical Literature—and Viewpoints in JAMA Internal Medicine
Robert Steinbrook, MD; Rita F. Redberg, MD, MSc
JAMA Internal Medicine
Original Investigation  |  February 25, 2013
Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus:  A Population-Based Matched Case-Control Study
Sonal Singh, MD, MPH; Hsien-Yen Chang, PhD; Thomas M. Richards, MS; et al.
JAMA Internal Medicine
Invited Commentary  |  March 5, 2013
Glucagonlike Peptide 1–Based Drugs and Pancreatitis:  Clarity at Last, but What About Pancreatic Cancer?
Comment on “Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus”
Belinda Gier, PhD; Peter C. Butler, MD
© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems